BiotechTube

ICL670/Deferasirox

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes, Transfusion Dependent Iron Overload

Trial Timeline

May 1, 2007 → —

NCT ID
NCT00481143

About ICL670/Deferasirox

ICL670/Deferasirox is a approved stage product being developed by Novartis for Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT00481143. Target conditions include Myelodysplastic Syndromes, Transfusion Dependent Iron Overload.

What happened to similar drugs?

6 of 18 similar drugs in Myelodysplastic Syndromes were approved

Approved (6) Terminated (7) Active (7)
✅decitabine + azacitidineEisaiApproved
✅DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅Epoetin betaRocheApproved
❌Placebo + Epoetin alfa + Placebo + Epoetin alfaJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00481143ApprovedCompleted

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Erlotinib HydrochlorideAstellas PharmaPhase 2
35
Decitabine + Decitabine + DecitabineEisaiPhase 2
35
Decitabine + Valproic AcidEisaiPhase 2
35
decitabine + decitabineEisaiPhase 2
35
decitabine + azacitidineEisaiApproved
35
DecitabineEisaiPhase 2
27
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
29
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
35
Subcutaneous DecitabineEisaiPhase 1
21
DecitabineEisaiPhase 2
35
Galunisertib + PlaceboEli LillyPhase 2/3
38
DSP-7888Sumitomo PharmaPhase 1/2
32
TP-0184Sumitomo PharmaPhase 1/2
24
DecitabineJohnson & JohnsonPhase 2
35
Epoetin alfaJohnson & JohnsonPhase 2
27
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
35